Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Clinical trial NCT05266846 · RECRUITING

Trial details

NCT number: NCT05266846
Sponsor: Hunan Province Tumor Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ALK Gene Mutation Lung Adenocarcinoma Immunotherapy

Start date: 2024-05-29
Primary completion: 2026-11-16
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.